Compare Paychex, Inc. (PAYX) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Paychex, Inc. trades at $109.38 (market cap $38.58B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Paychex, Inc. is far larger — about 5.2× Spyre Therapeutics Inc. Common Stock's market cap, and Paychex, Inc. pays a 4.39% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Paychex, Inc. for 56 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PAYX | SYRE | |
|---|---|---|
Market Cap | $38.58B | $7.35B |
Volume | 2,721,004 | 1,624,631 |
Sector | Industrials | Health |
52-Week High | $127.54 | $108.92 |
52-Week Low | $85.57 | $22.18 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $42.26B | $6.35B |
Dividend Yield | 4.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $106.26, up 1.55% today, with a bullish technical signal despite some bearish moving average indicators. The company reported a beat on Q2 2026 EPS of $1.34 versus $1.32 expected, continuing a trend of earnings outperformance. Revenue grew to $5.57B in 2025, with strong profitability margins including a 27.35% net income margin and 47.06% ROE. Recent news highlights dividend sustainability concerns amid a stock price decline, though the company maintains a solid financial position.
The outlook for PAYX is mixed; fundamentals remain robust with consistent earnings beats and high profitability, but investor sentiment is cautious due to valuation concerns and labor market exposure. Near-term price action hinges on Q3 2026 earnings and dividend coverage metrics. Risks include economic sensitivity and competitive pressures, while analyst consensus suggests modest upside to a $111 price target.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
